Study on the inhibition of non-small cell lung cancer mediated by chitosan-based gene carrier delivering STAT3-shRNA

Area of Science:

• Biomedical Engineering
• Molecular Biology
• Oncology

Background:

• Systemic chemotherapy and radiotherapy show limited efficacy and induce drug resistance in non-small cell lung cancer (NSCLC) postoperative treatment.
• Targeted gene therapy offers a promising alternative to overcome these limitations.

Purpose of the Study:

• To develop a novel non-viral gene delivery system for targeted therapy of NSCLC.
• To investigate the efficacy of STAT3 gene silencing using a Vitamin E Succinate-Chitosan-Histidine (VCH) gene carrier in NSCLC cells.

Main Methods:

• A STAT3-specific short hairpin RNA (shRNA) was constructed into a eukaryotic expression vector.
• A novel gene carrier, Vitamin E Succinate-Chitosan-Histidine (VCH), was synthesized and complexed with the plasmid DNA (pDNA).
• The VCH/pDNA nanoparticles were characterized for size and tumor-targeting capabilities via the enhanced permeability and retention (EPR) effect and endocytosis.

Main Results:

• VCH/pDNA nanoparticles demonstrated nanoscale dimensions and pH-responsive drug release in acidic tumor microenvironments.
• Gene delivery effectively downregulated STAT3 expression in NSCLC cells via RNA interference (RNAi).
• STAT3 inhibition significantly enhanced apoptosis and growth inhibition in NSCLC cells, mediated by the PI3K and mTOR signaling pathways.

Conclusions:

• The VCH gene carrier system is effective for targeted delivery and gene silencing of STAT3 in NSCLC.
• This novel gene therapy approach shows potential for improving NSCLC treatment outcomes by enhancing anti-tumor effects.
• The study highlights a promising strategy for developing non-viral gene carriers for clinical gene-targeted therapy.